From:
`Sent:
`To:
`Cc:
`
`Subject:
`Attachments:
`
`Scott McBride <scott.mcbride@bartlitbeck.com>
`Thursday, April 1, 2021 4:07 PM
`Park, Young J.; 'Cunning, II, Scott A.'; Modi, Naveen; Eisai-Lemborexant-PGR-PH
`Amanda Onorato; Meg Fasulo; External user - Adam Mortara; Crompton, Elizabeth M.;
`Regan, Crystal L.
`[EXT] RE: PGR2021-00047 - substitution of parties and counsel
`assignment-pat-55754-459.pdf; Notice.pdf
`
`Young,
`
`We will not be providing that information. It is not required in order for Eisai to
`inform us whether it will oppose our request for substitution. The patent
`assignment has been officially recorded with the PTO (attached).
`
`We will be emailing the Board tomorrow morning. Let us know by COB today
`whether Eisai objects or not and provide us with day/times for a potential call with
`the Board early next week.
`
`Regards,
`Scott
`
`
`
`
`
`
`(cid:3)J
`
`
`
`. Scott McBride | p: 312.494.4436 | Scott.McBride@BartlitBeck.com | Courthouse Place, 54 West Hubbard Street, Chicago, IL 60654
`This message may contain confidential and privileged information. If it has been sent to you in error, please reply to advise the sender of the error and then immediately
`delete this message.
`BartlitBeck LLP(cid:3)
`
`(cid:3) F
`
`rom:(cid:3)Park,(cid:3)Young(cid:3)J.(cid:3)<youngpark@paulhastings.com>(cid:3)(cid:3)
`Sent:(cid:3)Thursday,(cid:3)April(cid:3)1,(cid:3)2021(cid:3)14:44(cid:3)
`To:(cid:3)Scott(cid:3)McBride(cid:3)<scott.mcbride@bartlitbeck.com>;(cid:3)'Cunning,(cid:3)II,(cid:3)Scott(cid:3)A.'(cid:3)<scottcunning@parkerpoe.com>;(cid:3)Modi,(cid:3)
`Naveen(cid:3)<naveenmodi@paulhastings.com>;(cid:3)Eisai(cid:882)Lemborexant(cid:882)PGR(cid:882)PH(cid:3)<Eisai(cid:882)Lemborexant(cid:882)PGR(cid:882)PH@paulhastings.com>(cid:3)
`Cc:(cid:3)Amanda(cid:3)Onorato(cid:3)<amanda.onorato@bartlitbeck.com>;(cid:3)Meg(cid:3)Fasulo(cid:3)<meg.fasulo@bartlitbeck.com>;(cid:3)External(cid:3)user(cid:3)(cid:882)(cid:3)
`Adam(cid:3)Mortara(cid:3)<adam@mortaralaw.com>;(cid:3)Crompton,(cid:3)Elizabeth(cid:3)M.(cid:3)<elizabethcrompton@parkerpoe.com>;(cid:3)Regan,(cid:3)
`Crystal(cid:3)L.(cid:3)<crystalregan@parkerpoe.com>(cid:3)
`Subject:(cid:3)RE:(cid:3)PGR2021(cid:882)00047(cid:3)(cid:882)(cid:3)substitution(cid:3)of(cid:3)parties(cid:3)and(cid:3)counsel(cid:3)
`
`ear(cid:3)Scott,(cid:3)
`
`(cid:3)D
`
`(cid:3)T
`
`hank(cid:3)you(cid:3)for(cid:3)sending(cid:3)us(cid:3)the(cid:3)March(cid:3)24,(cid:3)2021(cid:3)agreement(cid:3)and(cid:3)identifying(cid:3)substitute(cid:3)counsel.(cid:3)(cid:3)(cid:3)
`
`Page 1 of 9
`
`1
`
`EISAI EXHIBIT 1042
`Eisai v. Crystal Pharm.
`PGR2021-00047
`
`

`

`(cid:3)P
`
`(cid:3)S
`
`incerely,(cid:3)
`Young(cid:3)
`(cid:3)(cid:3)
`
`lease(cid:3)also(cid:3)send(cid:3)us(cid:3)a(cid:3)copy(cid:3)of(cid:3)the(cid:3)“Patent(cid:3)Purchase(cid:3)Agreement(cid:3)(‘Purchase(cid:3)Agreement’)”(cid:3)which(cid:3)the(cid:3)document(cid:3)you(cid:3)sent(cid:3)
`purports(cid:3)to(cid:3)be(cid:3)a(cid:3)part(cid:3)of(cid:3)(see(cid:3)Whereas(cid:3)clause)(cid:3)and(cid:3)which(cid:3)was(cid:3)said(cid:3)to(cid:3)contain(cid:3)consideration(cid:3)for(cid:3)the(cid:3)transfer(cid:3)(see(cid:3)first(cid:3)
`numbered(cid:3)paragraph).(cid:3)(cid:3)Please(cid:3)also(cid:3)let(cid:3)us(cid:3)know(cid:3)if(cid:3)there(cid:3)are(cid:3)any(cid:3)other(cid:3)agreements(cid:3)that(cid:3)potentially(cid:3)bear(cid:3)on(cid:3)Crystal(cid:3)
`Pharmaceutical’s(cid:3)interest(cid:3)in(cid:3)the(cid:3)’779(cid:3)patent(cid:3)or(cid:3)these(cid:3)proceedings.(cid:3)(cid:3)(cid:3)
`
`Young J. Park | Partner, Litigation Department
`Paul Hastings LLP | 200 Park Avenue, New York, NY 10166 | Direct: +1.212.318.6861 | M
`+1.212.318.6000 | Fax: +1.212.230.7761 | youngpark@paulhastings.com |
`www.paulhastings.com (cid:3)
`
`(cid:3)
`
`(cid:3)(cid:3)(cid:3)(cid:3) F
`
`(cid:3)Y
`
`oung,
`
`rom:(cid:3)Scott(cid:3)McBride(cid:3)<scott.mcbride@bartlitbeck.com>(cid:3)(cid:3)
`Sent:(cid:3)Wednesday,(cid:3)March(cid:3)31,(cid:3)2021(cid:3)8:33(cid:3)PM(cid:3)
`To:(cid:3)Park,(cid:3)Young(cid:3)J.(cid:3)<youngpark@paulhastings.com>;(cid:3)'Cunning,(cid:3)II,(cid:3)Scott(cid:3)A.'(cid:3)<scottcunning@parkerpoe.com>;(cid:3)Modi,(cid:3)
`Naveen(cid:3)<naveenmodi@paulhastings.com>;(cid:3)Eisai(cid:882)Lemborexant(cid:882)PGR(cid:882)PH(cid:3)<Eisai(cid:882)Lemborexant(cid:882)PGR(cid:882)PH@paulhastings.com>(cid:3)
`Cc:(cid:3)Amanda(cid:3)Onorato(cid:3)<amanda.onorato@bartlitbeck.com>;(cid:3)Meg(cid:3)Fasulo(cid:3)<meg.fasulo@bartlitbeck.com>;(cid:3)External(cid:3)user(cid:3)(cid:882)(cid:3)
`Adam(cid:3)Mortara(cid:3)<adam@mortaralaw.com>;(cid:3)Crompton,(cid:3)Elizabeth(cid:3)M.(cid:3)<elizabethcrompton@parkerpoe.com>;(cid:3)Regan,(cid:3)
`Crystal(cid:3)L.(cid:3)<crystalregan@parkerpoe.com>(cid:3)
`Subject:(cid:3)[EXT](cid:3)RE:(cid:3)PGR2021(cid:882)00047(cid:3)(cid:882)(cid:3)substitution(cid:3)of(cid:3)parties(cid:3)and(cid:3)counsel(cid:3)
`
`
`Assignment is attached. Substitute counsel will be Bartlit Beck LLP. Meg Fasulo
`and myself. Additionally, Adam K. Mortara (not of Bartlit Beck) will be counsel as
`well.
`
`Please let us know tomorrow whether Eisai will oppose and provide us with
`days/times we can give to the Board in case they want a call.
`
`Regards,
`(other) Scott
`
`
`
`
`
`(cid:3)J
`
`
`
`. Scott McBride | p: 312.494.4436 | Scott.McBride@BartlitBeck.com | Courthouse Place, 54 West Hubbard Street, Chicago, IL 60654
`This message may contain confidential and privileged information. If it has been sent to you in error, please reply to advise the sender of the error and then immediately
`delete this message.
`BartlitBeck LLP(cid:3)
`
`2
`
`(cid:3) P
`
`age 2 of 9
`
`

`

`From:(cid:3)Park,(cid:3)Young(cid:3)J.(cid:3)<youngpark@paulhastings.com>(cid:3)(cid:3)
`Sent:(cid:3)Wednesday,(cid:3)March(cid:3)31,(cid:3)2021(cid:3)19:20(cid:3)
`To:(cid:3)'Cunning,(cid:3)II,(cid:3)Scott(cid:3)A.'(cid:3)<scottcunning@parkerpoe.com>;(cid:3)Modi,(cid:3)Naveen(cid:3)<naveenmodi@paulhastings.com>;(cid:3)Eisai(cid:882)
`Lemborexant(cid:882)PGR(cid:882)PH(cid:3)<Eisai(cid:882)Lemborexant(cid:882)PGR(cid:882)PH@paulhastings.com>(cid:3)
`Cc:(cid:3)Amanda(cid:3)Onorato(cid:3)<amanda.onorato@bartlitbeck.com>;(cid:3)Meg(cid:3)Fasulo(cid:3)<meg.fasulo@bartlitbeck.com>;(cid:3)External(cid:3)user(cid:3)(cid:882)(cid:3)
`Adam(cid:3)Mortara(cid:3)<adam@mortaralaw.com>;(cid:3)Scott(cid:3)McBride(cid:3)<scott.mcbride@bartlitbeck.com>;(cid:3)Crompton,(cid:3)Elizabeth(cid:3)M.(cid:3)
`<elizabethcrompton@parkerpoe.com>;(cid:3)Regan,(cid:3)Crystal(cid:3)L.(cid:3)<crystalregan@parkerpoe.com>(cid:3)
`Subject:(cid:3)RE:(cid:3)PGR2021(cid:882)00047(cid:3)(cid:882)(cid:3)substitution(cid:3)of(cid:3)parties(cid:3)and(cid:3)counsel(cid:3)
`
`ear(cid:3)Scott,(cid:3)
`
`(cid:3)(cid:3)
`Thank(cid:3)you(cid:3)for(cid:3)your(cid:3)email(cid:3)regarding(cid:3)the(cid:3)current(cid:3)ownership(cid:3)of(cid:3)the(cid:3)’779(cid:3)patent.(cid:3)(cid:3)Please(cid:3)send(cid:3)us(cid:3)the(cid:3)patent(cid:3)assignment(cid:3)or(cid:3)
`other(cid:3)documentation(cid:3)that(cid:3)verifies(cid:3)the(cid:3)transfer(cid:3)of(cid:3)ownership(cid:3)of(cid:3)the(cid:3)’779(cid:3)patent(cid:3)from(cid:3)Crystal(cid:3)Pharmaceutical(cid:3)to(cid:3)Bergen(cid:3)
`Pharmaceuticals.(cid:3)(cid:3)To(cid:3)the(cid:3)extent(cid:3)any(cid:3)such(cid:3)document(cid:3)contains(cid:3)confidential(cid:3)information,(cid:3)we(cid:3)will(cid:3)treat(cid:3)it(cid:3)as(cid:3)confidential(cid:3)
`(consistent(cid:3)with(cid:3)the(cid:3)protective(cid:3)order(cid:3)with(cid:3)our(cid:3)motion(cid:3)to(cid:3)seal).(cid:3)(cid:3)We(cid:3)would(cid:3)also(cid:3)request(cid:3)identification(cid:3)of(cid:3)the(cid:3)proposed(cid:3)
`substitute(cid:3)counsel.(cid:3)(cid:3)(cid:3)
`(cid:3)(cid:3)
`Once(cid:3)we(cid:3)have(cid:3)this(cid:3)information,(cid:3)we(cid:3)should(cid:3)be(cid:3)in(cid:3)position(cid:3)to(cid:3)respond(cid:3)to(cid:3)your(cid:3)request.(cid:3)
`(cid:3)(cid:3)
`Sincerely,(cid:3)
`Young(cid:3)
`(cid:3)(cid:3)
`
`(cid:3)D
`
`Young J. Park | Partner, Litigation Department
`Paul Hastings LLP | 200 Park Avenue, New York, NY 10166 | Direct: +1.212.318.6861 | M
`+1.212.318.6000 | Fax: +1.212.230.7761 | youngpark@paulhastings.com |
`www.paulhastings.com (cid:3)
`
`(cid:3)
`
`(cid:3)(cid:3)(cid:3)(cid:3) F
`
`rom:(cid:3)Cunning,(cid:3)II,(cid:3)Scott(cid:3)A.(cid:3)<scottcunning@parkerpoe.com>(cid:3)(cid:3)
`Sent:(cid:3)Tuesday,(cid:3)March(cid:3)30,(cid:3)2021(cid:3)6:30(cid:3)PM(cid:3)
`To:(cid:3)Modi,(cid:3)Naveen(cid:3)<naveenmodi@paulhastings.com>;(cid:3)Eisai(cid:882)Lemborexant(cid:882)PGR(cid:882)PH(cid:3)<Eisai(cid:882)Lemborexant(cid:882)PGR(cid:882)
`PH@paulhastings.com>(cid:3)
`Cc:(cid:3)Amanda(cid:3)Onorato(cid:3)<amanda.onorato@bartlitbeck.com>;(cid:3)Meg(cid:3)Fasulo(cid:3)<meg.fasulo@bartlitbeck.com>;(cid:3)External(cid:3)user(cid:3)(cid:882)(cid:3)
`Adam(cid:3)Mortara(cid:3)<adam@mortaralaw.com>;(cid:3)Scott(cid:3)McBride(cid:3)<scott.mcbride@bartlitbeck.com>;(cid:3)Crompton,(cid:3)Elizabeth(cid:3)M.(cid:3)
`<elizabethcrompton@parkerpoe.com>;(cid:3)Regan,(cid:3)Crystal(cid:3)L.(cid:3)<crystalregan@parkerpoe.com>(cid:3)
`Subject:(cid:3)[EXT](cid:3)PGR2021(cid:882)00047(cid:3)(cid:882)(cid:3)substitution(cid:3)of(cid:3)parties(cid:3)and(cid:3)counsel(cid:3)
`
`(cid:3)S
`
`incerely,(cid:3)
`
`Page 3 of 9
`
`3
`
`ounsel,(cid:3)
`
`(cid:3)C
`
`(cid:3)(cid:3)
`As(cid:3)you(cid:3)may(cid:3)be(cid:3)aware,(cid:3)earlier(cid:3)this(cid:3)week(cid:3)the(cid:3)’779(cid:3)patent(cid:3)was(cid:3)assigned(cid:3)to(cid:3)a(cid:3)new(cid:3)owner,(cid:3)Bergen(cid:3)Pharmaceuticals(cid:3)LLC.(cid:3)(cid:3)In(cid:3)
`light(cid:3)of(cid:3)this(cid:3)change,(cid:3)Crystal(cid:3)Pharmaceutical(cid:3)and(cid:3)Bergen(cid:3)intend(cid:3)to(cid:3)approach(cid:3)the(cid:3)Board(cid:3)for(cid:3)authorization(cid:3)to(cid:3)move(cid:3)to(cid:3)
`substitute(cid:3)parties,(cid:3)substitute(cid:3)counsel,(cid:3)and(cid:3)re(cid:882)caption(cid:3)the(cid:3)case.(cid:3)(cid:3)(cid:3)
`(cid:3)(cid:3)
`Please(cid:3)let(cid:3)us(cid:3)know(cid:3)as(cid:3)soon(cid:3)as(cid:3)possible(cid:3)whether(cid:3)Eisai(cid:3)opposes(cid:3)such(cid:3)a(cid:3)request,(cid:3)and(cid:3)please(cid:3)provide(cid:3)us(cid:3)with(cid:3)dates(cid:3)and(cid:3)times(cid:3)
`that(cid:3)would(cid:3)work(cid:3)for(cid:3)a(cid:3)conference(cid:3)call(cid:3)with(cid:3)the(cid:3)Board(cid:3)late(cid:3)this(cid:3)week/early(cid:3)next(cid:3)week,(cid:3)if(cid:3)the(cid:3)Board(cid:3)thinks(cid:3)it(cid:3)necessary.(cid:3)(cid:3)(cid:3)
`
`

`

`(cid:3)S
`
`cott(cid:3)
`
`(cid:3)(cid:3)
`
`(cid:3) S
`
`cott A. Cunning
`Partner
`
`
`
`
`
`1400 K Street N.W. | Suite 1000 | Washington, DC 20005-2403
`Office: 202.854.2813 | Mobile: 202.306.4135 | Fax: 202.217.2771 | vcard | Map
`
`Visit our website at
`www.parkerpoe.com
`
`PRIVILEGED AND CONFIDENTIAL: This electronic message and any attachments are confidential property of the sender. The information is intended only for
`the use of the person to whom it was addressed. Any other interception, copying, accessing, or disclosure of this message is prohibited. The sender takes no
`responsibility for any unauthorized reliance on this message. If you have received this message in error, please immediately notify the sender and purge the
`message you received. Do not forward this message without permission. [ppab_p&c]
`
`******************************************************************************************
`This message is sent by a law firm and may contain information that is privileged or confidential. If you received
`this transmission in error, please notify the sender by reply e-mail and delete the message and any attachments.
`If you reply to this message, Paul Hastings may collect personal information including your name, business name
`and other contact details, and IP address. For more information about Paul Hastings’ information collection, privacy
`and security principles please click HERE. If you have any questions, please contact Privacy@paulhastings.com.
`
`******************************************************************************************
`This message is sent by a law firm and may contain information that is privileged or confidential. If you received
`this transmission in error, please notify the sender by reply e-mail and delete the message and any attachments.
`If you reply to this message, Paul Hastings may collect personal information including your name, business name
`and other contact details, and IP address. For more information about Paul Hastings’ information collection, privacy
`and security principles please click HERE. If you have any questions, please contact Privacy@paulhastings.com.
`
`Page 4 of 9
`
`4
`
`

`

`506580829
`
`03/29/2021
`
`PATENT ASSIGNMENT COVER SHEET
`
`Electronic Version v1.1
`Stylesheet Version v1.2
`
`EPAS ID: PAT6627610
`
`SUBMISSION TYPE:
`
`NEW ASSIGNMENT
`
`NATURE OF CONVEYANCE:
`
`ASSIGNMENT
`
`CONVEYING PARTY DATA
`
`CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD.
`
`RECEIVING PARTY DATA
`
`Execution Date
`
`03/24/2021
`
`source=Patent Assignment_US10759779#pages3.tif
`
`PROPERTY NUMBERS Total: 1
`
`Property Type
`
`Patent Number:
`
`10759779
`
`CORRESPONDENCE DATA
`
`(215)731-3751
`Fax Number:
`Correspondencewill be sent to the e-mail addressfirst; if that is unsuccessful, it will be sent
`using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.
`Phone:
`2157727316
`Email:
`patents@mmwr.com
`Correspondent Name:
`MONTGOMERY MCCRACKEN WALKER & RHOADS LLP
`AddressLine1:
`1735 MARKET STREET
`
`AddressLine 2:
`
`AddressLine 4:
`
`21ST FLOOR
`
`PHILADELPHIA, PENNSYLVANIA 19103
`
`NAME OF SUBMITTER:
`
`MARYANN BARUT
`
`SIGNATURE:
`
`DATE SIGNED:
`
`/Maryann Barut/
`
`03/29/2021
`
`Total Attachments: 3
`source=Patent Assignment_US10759779#page1 tif
`source=Patent Assignment_US10759779#pagec.tif
`
`Page 5 of 9
`
`506580829
`
`REEL: 055754 FRAME: 0459
`
`

`

`PATENT ASSIGNMENT
`
`s«
`This PATENT ASSICNMENT (4
`
`eat) dated as of Marek 24, 2021
`
`
`ive Date}, by and between Bergen Pharmaceuti
`
`with an address at [G00 N
`We:est Street Sudte 1200, Wooungton, Delaware 1986] oy
`oe" ‘and Crystal Fharraaceutical
`
`(Suzhou} Co., Lid., with an address at B4-301, Rintbay,“218hela Siyeey,uatea indastrial
`
`Park, Sug
`
`
`
`ou, China 215123 CAssignor}. Assignees and Assignor are eacha“Party”to this
`
`
`Assusmment and collectively they are the “Farties” to this Aasienment.
`
`
`WHEREAS, as part of a Patent Purchase Agr
`at
`(“Purchase Agreement”)
`
`entered into by and bebweaent é
`BYeecandneailotaAssignar desives iG sall, convey, as
`iG
`
`
`
`avid transferto Assig
`P Agsignor’s right, tile, and iuerest in arnd
`
`
`
`
`
`edhife A hereto inchiding theright te claim
`priority sherethom«antlPalli divisional osonitinuatior
`.contineation in part, reexaminations, foreign
`
`counterparts, patents issuing therefrom,
`andal reissues thereof and patent ef addition
`
`applications, andall registrations, and extensionsofterre. derivedtherefrom(collectively, the
`“Assigned Patents”).
`
`follows:
`
`NOW, THEREFORE, for good and valuable consisleration, the Parties agree as
`
`
`
`
`
`POVaNee,
`
`;
`i,
`
`:
`do and valuable consideration, inchiding as
`SEN
`cornent, the receiot ofPatch is hereby acknowledged, Assignor dus:
`
`AG
`provided in the Purcha
`
`
`
`hereby acll, convey, assign,“grant and transfer to Assignees Assignor’s entire riebt,
`tile and interest
`
`
`in and to the Assigned Patents. Such assizren
`ules, without Hmitatin, all rights to sue or
`
`
`otherwise recover for past, present and fiture infringement of se Assigned Patents, and ic
`>
`receive all darnages, payments, costs, and fees associated with the
`mont of such rights, as
`
`
`well as allrights to Hcense, aesien, pledge, and/or otherwise & oitsuchen Patents and to
`
`Clam priority and Gle for extennsions. and oeSees protect
`ates. Nott
`tenn
`
`ine foregoing, this Assignment will besconsinied a8 ani
`¢
`i
`and transfer (and not @ present ans
`seiek respect ti) @
`fhinisdiction in wh
`
`
`Nee, Asstenicnt anc transfer
`con
`
`
`
`
`and recordation of a necessary juried
`
`
`
`
` nor hereby autherizes and requests the Comoveaioner
`ste aged Ten tiery:s
`
`RS QA P CAMO
`
`other appheable governmental entity or registrar fo record
`
`mis, and to issue any ari all Assigned Patents ic
`
`
`tle and itterest
`in, fo. and ander the same.
`
`
`: mont with all applicable governmental
`
`aynid7venistears
`
`
`
`
`
`gned Patents.
`
`Page 6 of 9
`
`REEL: 055754 FRAME: 0460
`
`

`

`5o
`
`h ment shall imure to the benefit of and
`« upent the parties berets and therrespective successors and permitied assigns.
`be bind
`
`ument to be
`
`IN WRENESS WHEREGO, the andersigned have caused this As:
`ccuted as of the date above first oritten.
`
`AEATVBg
`SWAY
`Seth
`TY ys
`
`
`
`
`
`Name: Ales RiGts:
`Sa
`?
`.
`—
`Title: CEO
`.
`
`SHINY
`
`ANNES
`
`Page 7 of 9
`Page 7 of 9
`
`PATENT
`REEL: 055754 FRAME: 0461
`
`

`

`SCHEBULE ATO PATENT ASSIGNMENT
`
`| Patents & Applications |
`,
`eeennn
`
`WS TOPS779
`
`|
`
`ee2
`
`
`
`Page 8 of 9
`Page 8 of 9
`RECORDED: 03/29/2021
`
`PATENT
`REEL: 055754 FRAME: 0462
`
`

`

`MARCH 30, 2021
`
`PTAS
`
`MONTGOMERY MCCRACKEN WALKER & RHOADS
`LLP
`1735 MARKET STREET
`21ST FLOOR
`PHILADELPHIA, PA 19103
`
`506580829
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
`
`THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH
`OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE
`ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.
`
`PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION
`CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT
`AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE
`QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION
`BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT
`AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX
`1450, ALEXANDRIA, VA 22313.
`
`RECORDATION DATE: 03/29/2021
`
`REEL/FRAME: 055754/0459
`NUMBER OF PAGES: 4
`
`BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
`
`ASSIGNOR:
`CRYSTAL PHARMACEUTICAL (SUZHOU) CO.,
`LTD.
`
`DOC DATE: 03/24/2021
`
`ASSIGNEE:
`BERGEN PHARMACEUTICAL LLC
`1000 N WEST STREET
`SUITE 1200
`WILMINGTON, DELAWARE 19801
`
`FILING DATE: 01/30/2020
`APPLICATION NUMBER: 16777121
`ISSUE DATE: 09/01/2020
`PATENT NUMBER: 10759779
`TITLE: CRYSTALLINE FORM OF OREXIN RECEPTOR ANTAGONIST, PROCESSES FOR
`PREPARATION THEREOF AND USE THEREOF
`
`ASSIGNMENT RECORDATION BRANCH
`PUBLIC RECORDS DIVISION
`
`Page 9 of 9
`
`